THE EFFICACY OF CURRENT TREATMENTS FOR NON-ALCOHOLIC FATTY LIVER DISEASE: A SYSTEMATIC REVIEW

Abstract

Non-alcoholic fatty liver disease (NAFLD) stands as the most prevalent chronic liver ailment, characterized by intricate pathogenetic mechanisms and a multifaceted etiology. A multitude of pathophysiological mechanisms contribute to the development of NAFLD, including oxidative stress, compromised mitochondrial metabolism, inflammation, gut microbiota dysregulation, and interactions within the brain-liver-axis influencing hepatic lipid metabolism. Novel therapeutic strategies targeting these pivotal pathways along the pathophysiological cascade have emerged, encompassing medications such as peroxisome proliferator-activated receptor (PPAR) agonists, glucagon-like peptide-1 (GLP-1) agonists, sodium/glucose transport protein 2 (SGLT2) inhibitors, foresaid X receptor (FXR) agonists, probiotics, and symbiotics. Future endeavors in biomedical research should prioritize investigating the intricate relationship between the microbiome, liver metabolism, and inflammatory response, as well as the systemic ramifications of metabolic syndrome.